Use the hyperlinks, where available to access additional clinical trial information.
A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations
Beijing InnoCare Pharma Tech Co., Ltd.
This is an open-label trial to evaluate ICP-192 in patients with advanced solid tumours and FGFR gene alterations. It consists of two parts: Part I dose escalation, and Part II dose expansion. Part I will consist of patients with advanced solid tumours, and they will be treated with ICP-192 following the "3+3" dose escalation scheme. Part II will consist of patients with urothelial carcinoma or cholangiocarcinoma with FGFR gene alterations, and they will be treated with a singe dose of ICP-192 as defined from Part I.